Comparative Study of Clinico-hematological Features, Molecular Spectrum and Response to Imatinib in Chronic Myelogenous Leukemia Patients: Pediatric and Adolescent Versus Adults
- 94 Downloads
Chronic myelogenous leukemia (CML) is a rare disease in children, accounting for approximately 3% of leukemias in children and adolescents, with an annual incidence of 1 case per million children in western countries. This study was conducted, at PGIMER, Chandigarh. Ninety eight patients, 48 in children and adolescents group, and 50 in adult group were included in the study. Their hematological profiles along with the bone marrow findings were analyzed. The diagnosis of CML was confirmed by cytogenetics and/or molecular analysis. The complete hematological response (CHR) was analyzed at 3 months and cytogentic response (CgR) at 12 months after starting imatinib therapy. Compared to adults, pediatric and adolescent patients were more symptomatic at presentation (93.5 vs. 75%). Among symptomatic patients, massive splenomegaly (>10 cm), higher total leucocyte and platelet counts were seen more frequently in pediatric patients. The most common transcript in both groups was e14a2. The distribution of pediatric and adolescent cases in Sokal, Hasford and EUTOS score, showed only statistically significant difference for low risk Sokal group, which had more patients in pediatric group. Compared to adults, pediatric and adolescent patients had similar CHR rate (91.3 vs. 92%), but showed lesser major CgR rate (90.9 vs. 95.5%) however, this was not statistically significant.
KeywordsChronic myelogenous leukemia Pediatric Adolescent Adult
Compliance with Ethical Standards
Conflict of interest
There are no conflict of interest to declare.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 3.Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S et al (2012) Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97:1029–1035CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W et al (eds) SEER cancer statistics review, 1975–2007, National Cancer Institute. Bethesda, MD. http://www.seer.cancer.gov/csr/1975-2007
- 5.Horner MJ, Ries LAG (2007) Leukemia. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (eds) SEER survival monograph: cancer survival among adults: U.S. SEER program, 1988–2001, patient and tumor characteristics. National Cancer Institute, SEER program, NIH, 07-6215Google Scholar
- 6.Vardiman JW, Melo JV, Baccarani M, Thiele J (2008) Chronic myelogeneous leukemia, BCR-ABL1 positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (eds) World Health Organization classification of tumours of haemopoietic and lymphoid tissues. IARC Press, Lyon, pp 32–37Google Scholar
- 11.National Comprehensive Cancer Network (2012). NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Version 3. 2013. http://www.nccn.org
- 18.Suttorp M, Millot F (2010) Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematol Am Soc Hematol Educ Program 2010:368–376Google Scholar
- 21.Suttorp M, Glauche I, Salas DG, Tauer JT, Nowasz C, Thiede C (2013) Scoring systems for predicting outcome of chronic myeloid leukemia in adults are poorly informative in pediatric patients treated with imatinib. 55th ASH, New Orleans, Dec 7–10, 2013: abstract no. 2725Google Scholar
- 23.Mahon FX, Rea D, Guilhot F et al (2009) Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients. Blood 114:859 (ASH Annual Meeting Abstract) Google Scholar